全球核因子 κB 轻链增强子 (NF-κB) 抑制剂市场 – 行业趋势和 2030 年预测

核因子 κB 轻链增强子 (NF-κB) 抑制剂市场分析及规模

癌症人口的增加和寻求新疗法的比率的上升可以作为核因子 κ 轻链增强剂活化 B 细胞 (NF-κB) 抑制剂市场增长的积极迹象。除此之外，强大的研发活动也可以提高市场地位。目前，许多公司正在该领域开展工作，创建了一条由大约 12 种以上的活性产品组成的强大产品线。  

Data Bridge Market Research 分析了 2023-2030 年预测期内核因子 kappa 轻链增强子活化 B 细胞 (NF-κB) 抑制剂市场的增长率。在上述预测期内，核因子 kappa 轻链增强子活化 B 细胞 (NF-κB) 抑制剂市场的预期复合年增长率趋于 11% 左右。2022 年市场价值为 26 亿美元，到 2030 年将增长至 60 亿美元。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外，Data Bridge Market Research 团队策划的市场报告还包括深入的专家分析、患者流行病学、管道分析、定价分析和监管框架。

核因子 κB 轻链增强子 (NF-κB) 抑制剂市场范围和细分

​​​​​​​

Market Definition

NF-κB (Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells) is a transcriptase factor which involves a number of physiological activities cellular process that includes cell proliferation, apoptosis and inflammatory response. Numerous diseases such as tumor, inflammatory joints disorders and asthma involves a NF-κB pathways. NF-κB is the matter of active research among many pharmaceutical companies as a target for anti-cancer therapy.

Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells (NF-κB) Inhibitors Market Dynamics

Drivers

• Increasing Prevalence of Cancer

Cancer is a top cause of death globally, accounting for approximately 10 million deaths in 2020. The most common in 2020 were breast cancer which was around 2.26 million cases. Breast cancer is the most common type, with 290,560 new cases expected in the U.S. in 2022. The next most prevalent cancers are prostate cancer and lung cancer. There was an estimated 19.3 million new cancer cases (18.1 million excluding nonmelanoma skin cancer) and almost 10.0 million cancer deaths (9.9 million excluding nonmelanoma skin cancer) occurred in 2020 globally. Thus, this factor which increases the demand for nuclear factor kappa-light-chain-enhancer of activated b cells (NF-κB) further boosts market growth.

Opportunities

• Rising Clinical Development Associated with the Products

Several major players are indulging themselves in launching multiple products that will help in the growth of the market. For instance, Reata’s Bardoxolone Methyl is under development by Reata Pharmaceuticals in late clinical-stage and has received Sakigake priority review designation Japan for treating diabetic kidney disease (DKD). AnGes’s AMG0101 has completed the phase III trials (ointment) in Japan for Atopic Dermatitis. The same drug is under phase I trial for Low Back Pain due to Disc Degeneration in United States. MedDay Pharmaceuticals’ MD-1003 is under Phase III stage of development as the most favourable emerging therapy for the future. Catabasis’s Edasalonexent is being assessed for phase II clinical studies by Catabasis Pharmaceuticals. The potential candidate has been awarded orphan drug, fast track and rare pediatric disease designations for treating Duchenne muscular dystrophy (DMD). Thus, all these developments will lead to the growth of the market.

• Increasing Healthcare Expenditure And Government Support

With the rising prevalence of cancer, the growing awareness for the disease and the associated treatment is also expanding. Various government initiatives tend to provide better and more convenient treatments combined with favourable reimbursement policies that are expected to increase the industry growth. Furthermore, increasing acceptance of advanced therapies is projected to drive the market.

Restraints/Challenges

• High Cost of Treatment

The rising expenditure associated with the medications impede the market growth. Several genetic drugs cost high, and people in highly developing and underdeveloped countries cause the under treatment of numerous patients. This hinders the market growth.

This nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) inhibitors market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) inhibitors market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells (NF-κB) Inhibitors Market Scope

The nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) inhibitors market is segmented on the basis of drugs, indication, route of administration, end-user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drugs

• Denosumab
• Bortezomib

Indication

• Multiple Myeloma
• Giant Cell Tumor of Bone
• Hypercalcemia
• Others

Route of Administration

• Intravenous
• Subcutaneous
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells (NF-κB) Inhibitors Market Regional Analysis/Insights

The nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) inhibitors market is analyzed and market size insights and trends are provided by drugs, indication, route of administration, end-users and distribution channel as referenced above.

The major countries covered in the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) inhibitors market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America has been witnessing a positive growth for nuclear factor kappa-light-chain-enhancer of activated b cells (NF-κB) inhibitors market throughout the forecasted period because of the high incidence rate of cancer, increasing awareness and development activities for nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) inhibitors  therapeutics.

Asia-Pacific dominates the market because of the healthy improvement in healthcare infrastructure and huge economic development. Furthermore, the healthy improvement in healthcare infrastructure and economic boost the market growth.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells (NF-κB) Inhibitors Market Share Analysis

核因子 kappa 轻链增强剂活化 B 细胞 (NF-κB) 抑制剂市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对核因子 kappa 轻链增强剂活化 B 细胞 (NF-κB) 抑制剂市场的关注有关。

核因子 κ 轻链增强子活化 B 细胞 (NF-κB) 抑制剂市场的主要参与者包括：

• 赛诺菲（法国）
• 辉瑞公司（美国）
• 葛兰素史克公司 (英国)
• 诺华公司（瑞士）
• AbbVie Inc.（美国）
• F. Hoffmann-La Roche Ltd.（瑞士）
• Mylan NV（美国）
• Teva Pharmaceutical Industries Ltd.（以色列）
• 费森尤斯卡比公司（德国）
• Dr. Reddy's Laboratories Ltd（印度）
• 默克公司（美国）
• Apotex Inc（加拿大）
• 安进公司（美国）
• AnGes, Inc.（日本）

SKU-52843